Cynaropicrin Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

346.37

DMSO: 50mg/mL (144.35mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C19H22O6

C=C(CO)C(O[C@@H](CC([C@H](C[C@@H]1O)[C@@H]([C@H]2OC3=O)C1=C)=C)[C@H]2C3=C)=O

35730-78-0

TNF-alpha
NO Synthase
IL Receptor

Cynaropicrin strongly inhibited TNF-alpha release from lipopolysaccharide-stimulated murine macrophage, RAW264.7 cells, and differentiated human macrophage, U937 cells, proved to produce notable amount of TNF-alpha. It also potently attenuated the accumulation of NO released from lipopolysaccharide- and interferon-gamma-stimulated RAW264.7 cells in a dose-dependent manner. In addition, the immunosuppressive effects of the compound on lymphocyte proliferation in response to mitogenic stimuli were examined. Cynaropicrin also dose-dependently suppressed the proliferation of lymphocytes from splenocytes and interleukin-2-sensitive cytotoxic T lymphocyte, CTLL-2 cells, stimulated by lipopolysaccharide, concanavalin A, phytohemagglutinin and interleukin-2. However, treatment with sulphydryl compound, L-cysteine, abrogated all these inhibitory effects.

Apoptosis; TNF; Immunology/Inflammation; Immunology/Inflammation